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ABSTRACT 
 
OBJECTIVE: The objective of this systematic review is to determine whether or not ceftobiprole is a 
safe and effective treatment for complicated skin and skin structure infections 
 
STUDY DESIGN: Review of all English language primary randomized controlled trials from 1996-
2010 
 
DATA SOURCES: Three randomized controlled trials were found using Pubmed and Cochrane 
databases 
 
OUTCOMES MEASURES: Skin or skin-structure infection cure with ceftobiprole intervention and 
adverse effects of this new pharmaceutical. Cure or failure to cure skin infection was determined based 
on both clinical and microbiological assessment. Adverse events were measured based on patient 
reports, clinician reports, labs, and vital sign assessment. 
 
RESULTS: Noel, Strauss et al. found statistically significant cure rates of complicated skin and skin-
structure infections with intervention of ceftobiprole compared to the standard control arm. Noel, Bush 
et al. found similar results when comparing ceftobiprole with the control arm. Both studies concluded 
that ceftobiprole was non-inferior to the leading treatment for complicated skin infections, and caused 
complete microbiological and clinical resolution of complicated skin infections. Schmitt-Hoffmann et 
al. concluded that ceftobiprole was safe for human consumption with no severe adverse effects noted. 
 
CONCLUSIONS: Cefrobiprole is comparable to vancomycin in both safety and effectiveness for 
treatment for skin and skin-structure infections 
 
KEY WORDS: Ceftobiprole, Skin infections; Skin structure infections, BAL5788 
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INTRODUCTION 
 An uncomplicated skin infection is the colonization of epidermal and dermal tissue with a 
parasitic pathogen. Complicated skin infections, as defined by Noel, Strauss et al, involve the 
subcutaneous tissue or require significant surgical intervention and one or more of the following: a 
wound infection, an abscess, or cellulitis.1 The most common pathogens causing skin and skin-structure 
infections include Streptococcus pyogens, Staphylococcus aureus, and recently, an increase of 
methicillin-resistant Staphylococcus aureus (MRSA). Treatment of complicated skin and skin-structure 
infections typically begins with empiric broad-spectrum antibiotics such as vancomycin, which is then 
tailored to a more narrow spectrum antibiotic based on sensitivity results. This review evaluates three 
randomized controlled trials that compare ceftobiprole, a novel antibiotic, to standard treatment with 
vancomycin for the treatment of complicated skin and skin-structure infections.  
 Ceftobiprole is an investigational novel pyrrolidinone cephalosporin still in clinical trials and 
unavailable in the Unites States.1 It is a broad-spectrum anti-MRSA antibiotic developed in 2004 by 
Basilea Pharmaceuticals and further developed and researched by Johnson and Johnson 
Pharmaceuticals. It shows activity against multiple pathogens including methicillin-resistant 
Staphylococcus aureus (MRSA), Enterobacteriaceae and Pseudomonas aeruginosa. The research 
articles used in this review studied the safety and efficacy of this novel antibiotic on complicated skin 
infections. 
 The diagnosis and treatment of complicated skin infections is within a physician assistant's 
scope of practice. Physician assistants are involved in care in multiple specialties that regularly treat  
patients with skin infections. Some of these include Dermatology, Family Medicine, Emergency 
Medicine, Pediatrics, Internal Medicine and Surgery. Because complicated skin infections occur 
commonly, physician assistants must stay abreast of changes and advancements in treatment options.  
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 The incidence of complicated MRSA related skin infections is showing an upward trend. MRSA 
is now responsible for 60% of purulent skin and soft tissue infections in patients presenting to 
emergency rooms in the United States.4 MRSA infections alone cost the healthcare system an estimated 
$830 million- $9.7 billion in 2005 alone and were responsible for 278,203 hospitalizations in 2005. 4,5 
 In the coming years, physician assistants are expected to encounter multiple skin infections with 
MRSA as a main causative pathogen. According to Graham et al's population based survey, 95 million 
Americans carry S. aureus in their noses.5 Of these, 2.5 million (2.6% of carriers) carry MRSA.5 The 
incidence of complicated MRSA infections is also increasing over time. Between 1999 and 2005, the 
estimated number of S. aureus related hospitalizations increased 62%, from 294,570 to 477,927.5 The 
number of serious complicated skin infections requiring hospitalizations is also increasing. Between 
1999 to 2005, the estimated number of MRSA-related hospitalizations more than doubled, from 
127,036 to 278,203.5 For these reasons, physician assistants must be aware of all potential ways to treat 
complicated skin infections caused by an increasingly common MRSA pathogen.  
 Because MRSA has become an increasingly ubiquitous, physician assistants must consider the 
possibility of MRSA as a causative agent in all skin infections and treat accordingly with a broad 
spectrum antibiotic until further culture and sensitivity is available. Currently, the most commonly  
used medication to treat these infections is vancomycin. However,  new evidence  from Noel et al 
suggests that ceftobiprole may be an effective alternative to vancomycin in treating complicated skin 
infections.  
 Ceftobiprole was developed in an effort to create more new agents with reliable activity against 
MRSA. The trials selected by the author compare ceftobiprole to vancomycin, the current standard of 
care for the treatment of skin infections due to gram positive bacteria in which methicillin resistance is 
a significant concern.1 
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OBJECTIVE 
 The objective of this selective EBM review is to determine whether or not ceftobiprole is a safe 
and effective treatment for complicated skin and skin-structure infections. 
 
METHODS 
 Selected articles included adults 18 years of age and older with complicated skin and skin-
structure infections. Interventions used varied by the study. Two studies examined the efficacy of 
ceftobiprole by comparing ceftobiprole with vancomycin or vancomycin plus ceftazidime and one 
study examined the safety of ceftobiprole. In the Noel, Bush et al. study, the intervention involved 
combining ceftobiprole plus placebo vs. vancomycin plus ceftazidine.2 Noel, Stauss et al. intervene by 
giving vancomycin vs ceftobiprole.1 Outcomes measured included cure of skin infection defined as 
“resolution of all signs and symptoms of the infection or improvement to such an extent that no further 
antimicrobial therapy was necessary,” and presence of significant adverse events.1 In Schmitt-Hoffman 
et al (2004), safety was assessed by giving participants either placebo BID, 500 mg ceftobiprole BID or 
750 mg ceftobiprole BID.3 The main focus of this study was to determine safety of the drug by 
assessing adverse events including serious adverse events. 
 Three randomized controlled studies were used for this systematic review. The author 
performed searches on Pubmed and Cochrane databases, using key words “ceftobiprole” and 
“BAL5788,” and by limiting results to those written in English. Inclusion criteria consisted of  articles 
published in peer-reviewed journals and were chosen based on outcomes significant to the patient. 
Articles were excluded if performed before 1996 or if participants were under age of 18. Both Noel et 
al. studies used confidence intervals (CI) to determine significance. The Schmitt-Hoffmann et al study, 
which examined the safety of ceftobiprole used number needed to harm (NNH) to assess adverse 
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effects of the drug at different doses versus a placebo. Table 1 demonstrates the demographics used in 
the studies examined. 
Table 1: Demographics of included studies 
Study Type # pts Age 
(yrs) 
Inclusion 
Criteria 
Exclusion 
Criteria 
W/D Interventions 
Noel GJ, 
Bush K et 
al (2008) 
1 
 
RCT* 
 
784 
 
18-91 
Adults 18 years 
or older who 
have a clinical 
diagnosis of 
complicated 
skin and skin 
structure 
infections 
caused by 
documented or 
suspected 
Gram-positive 
bacteria 
Pts with allergic 
reactions to 
cephalosporins or 
vancomyocin, 
pregnant or lactating 
women, 
neutropenia, HIV 
infected with low 
CD4 count, diabetic 
foot infections, 
osteomyelitis, 
animal or human 
bites, recent 
antimicrobial 
treatment x >24 
hours in last 7 days 
 
118 
Ceftobiprole 500 
mg BID x 7-14 days 
or Vancomycin 1g 
BID x 7-14 days 
Noel GJ, 
Strauss RS. 
et al 
(2008) 
2 
 
RCT 
 
828 
 
19-92 
Adults 18 yrs or 
older  
diagnosed with 
skin or skin 
structure 
infection  
Pts with foreign 
body infection, 
osteomyelitis, 
critical limb 
ischemia, septic 
arthritis 
 
66 
Ceftobiprole 500 
mg infusion over 
120 min q 8 hrs x 7-
14 days + Placebo 
infusion over 60 
min q 12 hrs x 7-14 
days or Vancomycin 
1 g infusion over 60 
min q 12 hrs x 7-14 
days + Cetazidine 1 
g infusion over 120 
min q 8 hrs x 7-14 
days 
Schmitt-
Hoffman 
(2004) 
3 
 
RCT 
 
16 
 
19-38 
>18 yrs 
Completed 
medical exam 
within normal 
limits 
Completed medical 
exam outside of 
normal limits 
 
0 
Placebo BID x 8 
days or 
Ceftobiprole 500 
mg BID x 8 days or 
Ceftobiprole 750 
mg BID x 8 days 
RCT = Randomized Controlled Trial 
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OUTCOMES MEASURED 
 Outcomes measured in this review include efficacy of ceftobiprole and safety of ceftobiprole. 
Efficacy, in both Noel et al studies, was measured by categorizing outcomes dichotomously into either 
skin infection cure or failure.1,2 Cure was defined as a complete resolution of all symptoms of the skin 
and skin-structure infection or improvement to such an extent that no further antimicrobial therapy was 
necessary.1 Failure was defined as a need for further treatment with a non-study drug or discontinuation 
of the study drug after three days secondary to ineffectiveness.1,2 
 Efficacy outcomes were measured in a standardized way through both microbiological 
assessment and clinical assessment. Microbiological assessment was measured via gram stain and 
culture of the skin and skin-structure infection site.1,2 The offending pathogen was identified in this 
way. At the end of treatment, a repeat gram stain and culture of infected are were taken. Negative gram 
stain and culture indicated cure of skin infection. Clinical outcomes were measured based on blinded 
clinician's assessment of the presence of signs and symptoms of skin infection. 
 Safety outcomes of ceftobiprole were measured by both Noel et al. studies and additionally by 
Schmitt-Hoffmann et al. Safety data was collected by Schmitt-Hoffmann et al. via blood samples for 
laboratory safety tests, vital signs and pt reported adverse events. An adverse event (AE) was defined as 
any adverse change that occurred after a patient was given a study drug. The Noel et al. studies mainly 
used patient reports for adverse reactions. 
 
RESULTS 
 All results in the three analyzed studies utilized dichotomous data: skin infection cured or not 
cured, and adverse effect or no adverse effect. Inclusion criteria for all studies included patients 18 
years of age or older. Both Noel et al. studies included only those who  were diagnosed with a 
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complicated skin or skin structure infection. Cellulitis cases were limited to 20% of the final patient 
population.1,2 Exclusion criteria included allergy or intolerability to cephalosporins or vancomycin, 
severe renal dysfunction, hepatic dysfunction, pregnant or lactating women, neutropenia, HIV with low 
CD4 counts, diabetic foot infections, animal or human bites, osteomyelitis, critical limb ischemia, 
septic arthritis, or systemic antibiotics for more than 24 hours in the last 7 days.1,2 
 Noel, Bush et al. reported a cure rate of 90.5% for the Ceftobiprole group and 90.2% for the 
group treated with vancomycin and ceftazidime which were proven to not be significantly different 
(95% CI, -4.4%, 3.9%).2 The relative risk reduction (RRR) was 0.003 and the absolute risk reduction 
(ARR) was 0.3%. This study determined the number needed to treat (NNT) was 333 participants 
(Table 2).2 
 Noel, Strauss et al determined a cure rate of 93.3% of participants being treated with 
ceftobiprole and 93.5% cure rate for those taking vancomycin which were not significantly different 
(95% CI, -4.2%, -4.9%).1 The relative risk reduction was 0.002 and the absolute risk reduction was 
found to be -0.2%. The number needed to treat for this study was -500 participants (Table 2).1 
 
Table 2. Efficacy of Ceftobiprole vs Vancomycin on skin infections 
  
Ceftobiprole 
 
Vancomycin 
Vancomycin 
+ 
ceftazidime 
95% CI* of 
difference in 
cure rates 
RBI* ABI* NNT* 
Noel, Bush, et 
al (2008) 
439/485  
(90.5%) 
N/A 220/244 
(90.2%) 
-4.4% - 3.9% 0.30% 0.30% 333 
Noel, Strauss, 
et al (2008) 
262/282 
(93.3%) 
259/277 
(93.5%) 
N/A -4.2% - 4.9% -0.20% -0.20% -500 
*CI = Confidence Interval, RBI = Relative Benefit Increase, ARR = Absolute Benefit Increase, NNT = 
Number Needed to Treat 
 
 Ceftobiprole was found to be effective against a number of common gram-positive bacteria 
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according to both Noel et al. studies. Two organisms cultured and followed in both studies was 
methicillin-resistant Staphylococcus aureus (MRSA) and methicillin-sensitive Staphylococcus aureus 
(MSSA).1,2  A summary of cure rates based on organism type can be found in Table 3. According to 
both studies, ceftobiprole was found to be non-inferior to vancomycin in treating both MSSA and 
MRSA infections.1,2 Noel, Strauss et al. found ceftobiprole cured 91.8% of MRSA infections and 
vancomycin cured 90.0% of cases which was not significantly different (95% CI, -8.4%, 12.1%).1 
Noel, Bush et al also found no significant difference between ceftobiprole and vancomycin when 
treating MRSA.2 This study reported 89.7% MRSA cure rate for ceftobiprole and 86.1% cure rate of 
MRSA in the vancomycin group which is not significantly different (95% CI, -8.0%, 19.7% ) (Table 
3).2 
 
                             Table 3. Cure rates for Staph. aureus infections                      
 Study Ceftobiprole 
group 
Control group 
(Vancomycin) 
95% CI 
MRSA Noel, Strauss et 
al. (2008) 
56/61 
(91.8%) 
54/60  
(90.0%) 
-8.4, 12.1 
Noel, Bush et 
al. (2008) 
78/87 
(89.7%) 
31/36  
(86.1%) 
-8.0, 19.7 
MSSA Noel, Strauss et 
al. (2008) 
121/126 
(96.0%) 
108/112 
(96.4%) 
-5.2, 4.4 
Noel, Bush et 
al. (2008) 
150/160 
(93.8%) 
84/90  
(93.3%) 
-5.8, 8.2 
  MRSA = Methicillin-resistant Staphylococcus aureus 
  MSSA = Methicillin-sensitive Staphylococcus aureus 
 
 
 Adverse events were also studied in the three randomized control trials. Noel, Strauss et al. 
reported 52% rate of adverse events in the ceftobiprole group and 51% rate of adverse events in the 
Vancomycin group.1 The relative risk increase (RRI) was 0.02 and the absolute risk increase (ARI) was 
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0.01.1 The number needed to harm in this study was 100 participants (Table 4).1 
 The Noel, Bush et al. study reported an adverse event rate of 56% in the ceftobiprole group and 
a 57% rate of adverse event rate for the vancomycin plus ceftazidime group.2 The relative risk increase 
(RRI) was -0.02 and the absolute risk increase (ARI) was -0.01.2 The number needed to harm (NNH) in 
this group was also 100 participants (Table 4).2 
 The final study, Schmitt-Hoffmann et al., reported a rate of 83% adverse events in the 
ceftobiprole group and 50% adverse event rate in the placebo group. The reported relative risk increase 
(RRI) was 0.66 and the absolute risk increase was 0.33.3 The number needed to harm in this study was 
3 participants (Table 4).3  
 
     Table 4. Incidences of at least one adverse event in Ceftobiprole and Control groups 
 Ceftobiprole Control group RRI* ARI* NNH* 
Noel, Strauss et 
al. (2008) 
203/389 
(52%) 
193/382 
(51%) 
2% 1% 100 
Noel, Bush et al. 
(2008) 
304/543 
(56%) 
159/279 
(57%) 
-2% -1% -100 
Schmitt-
Hoffmann et al. 
5/6 
(83%) 
2/4** 
(50%) 
66% 33% 3 
                *RRI = Relative Risk Increase, ARI = Absolute Risk Increase, NNH = Number Needed to                  
        Harm 
                **Schmitt-Hotffmann compared Ceftobiprole to placebo 
 
 The incidence of serious events were also recorded in all three analyzed studies. Serious adverse 
events were defined as any experience that was life threatening, required hospitalization, or resulted in 
death.1,2 In Noel, Strauss et al. 6% of participants in the ceftobiprole group and 6% of participants in 
the vancomycin group also reported serious adverse events.1 In Noel, Bush et al. 7% experienced 
serious adverse events while taking ceftobiprole and 9% while taking vancomycin.2 The Schmitt-
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Hoffmann et al. study reported no serious adverse events (Table 5).3 
Table 5. Incidence of serious adverse events (AE) 
 Ceftobiprole Vancomycin 
Noel, Strauss et al. 
(2008) 
24/398 
(6%) 
23/382 
(6%) 
Noel, Bush et al. (2008) 39/543 
(7%) 
24/279 
(9%) 
Schmitt-Hoffmann et 
al. 
0/16 
(0%) 
N/A 
  
 Losses to follow up were recorded and all individuals leaving the study were accounted for. In 
Noel, Strauss et al. 15% of the participants were lost to follow up.1 The most common reasons for loss 
to follow up included adverse events or concomitant illness (35 patients), non-cooperation (28 
patients), and administrative issues (21 patients).1 In Noel, Bush et al. 8% discontinued, with most 
common reason cited as loss to follow up accounting for 3%.2 There were no patients lost to follow up 
in Schmitt-Hoffmann et al.3 
 
DISCUSSION 
 One limitation of the Schmitt-Hoffmann et al. safety trial was the duration of treatment. 
Ceftobiprole was administered for 8 days in this study and adverse effects only measured during that 
time. The Noel et al. studies used ceftobiprole for an average of 9.0 days and a range of 7-14 days.1,2 
More adverse events may have occurred if the drug was administered for a longer duration. In order to 
adequately assess safety of a drug it should be tested at the maximum amount of time potentially used 
by clinicians. This way delayed adverse events can be more accurately measured and thus safety of the 
drug can be determined. 
 Another limitation is the clinical cure of infection. This is, by nature, subjective and could have 
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wide variation based on clinician assessment. The standard used for clinical cure was defined as 
“resolution of all signs and symptoms of infection,” which may have a wide range of meaning and 
provider to provider dissonance. There is no way to fully eliminate provider subjectivity and this is a 
perceived weakness in the study. 
 Another limitation of this review is the fact that both of the main studies determining efficacy 
were performed by the same lab and headed by the same researcher, Gary Noel. There could be built in 
bias in reporting results based on researchers desire to produce positive efficacy results. In addition, 
both of the main studies were funded by Johnson & Johnson Pharmaceuticals who have an invested 
interest in finding an alternative to vancomycin which is currently mainly produced by a Hospira, a 
competing Pharmacutical company. More studies need to be performed by other non-biased researchers 
in order to determine true effectiveness.  
 At the time this article was written, ceftobiprole was available in Canada and Switzerland but 
was under review by regulatory authorities and still unavailable in the United States. More research is 
needed in order for ceftobiprole to be considered a safe and effective alternative to vancomycin and for 
it to be marketable as such. 
 One disadvantage to using this medication is that it can only be given intravenously. This limits 
its use to inpatient care only. In order for a patient to be discharged with a skin infection they need to be 
managed with a medication by mouth which in this case would require a medication change. Further 
research would need to be conducted to measure effectiveness of switching from ceftobiprole to a po 
medication to be taken upon discharge 
 
CONCLUSION  
 The evidence from these three clinical trials support the conclusion that ceftobiprole is as safe 
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and effective as vancomycin, the standard treatment for curing complicated skin and skin structure 
infections. The studies reviewed provide supporting evidence that intervention with ceftobiprole leads 
to complete resolution of complicated skin and skin structure infections, both microbiologically and 
clinically. The conclude that ceftobiprole may be considered a reasonable alternative to vancomycin or 
combination treatments in the event the patient is allergic to vancomycin or the bacteria is vancomycin 
resistant. 
 Ceftobiprole is proven effective against gram-positive pathogens, including Staphylococci 
which is a leading cause of complicated skin and soft tissue infections. It has also been proven effective 
against MRSA, which is a significant concern for health care providers treating complicated skin 
infections. 
 The evidence also shows that ceftobiprole is a safe agent for consumption by patients. Although 
multiple adverse effects were noted, minimal serious adverse effects were attributed to ceftobiprole in 
the studies performed. The incidence of adverse effects was on par with or less than the rate of adverse 
events for vancomycin. 
 Despite the limitations noted here, the reviewed studies present evidence that ceftobiprole is an 
effective alternative to vancomycin in treating gram positive complicated skin and skin-structure 
infections.  
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